Clicky

Vaccines

POP Biotechnologies and EuBiologics’ EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial
697 465 Merci

POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics (KOSDAQ: 206650). EuCorVac-19…

  • Merci
  • 0
  • 0

Moderna Finalizes Strategic Partnership with UK Government
1200 277 Robert

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the finalization of a strategic partnership with the UK government to establish a state-of-the-art mRNA research, development, and manufacturing facility in…

  • Robert
  • 0
  • 0

IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
1200 277 Merci

Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / May 18,…

  • Merci
  • 0
  • 0

Moderna to Host Annual Science and Technology Day on May 17, 2022
1200 277 Merci

CAMBRIDGE, MA / ACCESSWIRE / May 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that that it will host its in-person Science and Technology Day for…

  • Merci
  • 0
  • 0

Moderna Finalizes Strategic Partnership with Australian Government
1200 277 Tori

On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually CAMBRIDGE, MA / ACCESSWIRE / March 23, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering…

  • Tori
  • 0
  • 0

Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
1200 277 Merci

Endorsement to proceed given by the independent Data and Safety Monitoring Board based on preliminary Phase 2 safety and tolerability data Moderna expects to enroll approximately 34,000 participants in multiple countries RSV causes severe disease…

  • Merci
  • 0
  • 0

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
933 574 Jane

– Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains – Influenza candidate developed in collaboration with GSK within broad infectious disease vaccine program TÜBINGEN, GERMANY and BOSTON, MA /…

  • Jane
  • 0
  • 0

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
1200 277 Jane

Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union,…

  • Jane
  • 0
  • 0

Eyam Vaccines and Immunotherapeutics Welcomes New Board Members and Scientific Advisors
594 280 admin

VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / Eyam Vaccines and Immunotherapeutics is pleased to publicly announce the appointment of Elizabeth Varki Jobes and Dr. Terry Pearson to the Board of Directors, and the…

Empower Clinics Kai Medical Laboratory Becomes Approved Vaccine Provider
270 50 Jane

Kai Medical Laboratory is Approved to Administer the Pfizer and Janssen Vaccines and Opens COVID-19 Vaccine Drive-Through VANCOUVER, BC / ACCESSWIRE / November 8, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an…

  • Jane
  • 0
  • 0
  • 1
  • 2